Green Light from AG Bot for Unitary Patent in Europe

Published November 2014

Green Light from AG Bot for Unitary Patent in Europe

The Opinion of Advocate General Bot, regarding Spain’s actions (CJEU cases C-146/13 and C-147/13) that the Regulations surrounding the creating of the European Unitary Patent should be annulled, has been given today. It is the Opinion of AG Bot that the CJEU should dismiss Spain’s actions.

Spain pleaded that the proposed language scheme would be discriminatory to persons whose mother tongue was not German, French or English. Furthermore, that aspects of EU law had been breached in the arranging of the Regulation on the Unitary Patent and Unified Patent Court.

Today’s press release states that unitary protection “brings real benefit” over the current European Patent Convention, where the effects of European patents are determined by national laws. Furthermore, even though the language arrangements that have been selected under the regime may curtail the use of some European languages, they “pursue a legitimate objective of reducing translation costs”. To limit the number of languages for the European Unitary Patent will reduce costs, and furthermore, acknowledges the linguistic realities of the patent sector (German, French and English are the most popular spoken languages from which patent application in the EU originate, as well as the languages of most published scientific papers).

In both cases brought by Spain, AG Bot proposed that CJEU should dismiss Spain’s actions.

The opinion of the Advocate General is not binding on the CJEU, and judgements will be given at a later stage. However, it is unusual for the Court not to follow the Opinion of the AG. The Opinion signifies a green light for unitary patent protection in Europe.

Latest updates

Event - 12th November 2026

HGF Partners with PPTI for 'Designing Foods for Healthy Aging' Webinar

As healthy aging, metabolic health and weight management rise up the consumer agenda, food and nutrition businesses are increasingly looking beyond traditional product development and towards solutions that deliver measurable …

Event details

Basel Seminar: Seminar on the new EU Pharma Package and its implications for regulatory exclusivities in the EU

Venue – Der Teufelhof Basel, Switzerland We are pleased to invite you to our seminar on the new EU Pharma Package and its implications for regulatory exclusivities in the EU. …

Read article
Event - 28th October 2026

HGF Attending BMCS Antibody–Drug Conjugates 2026

HGF is pleased to announce that Dr Thomas Lonsdale, Patent Director, will be attending the BMCS Antibody–Drug Conjugates 2026 meeting, taking place on 19 November 2026 at GSK, Stevenage, UK. …

Event details

Hsu Min Chung Recognised in IAM Global Leaders 2027

HGF is delighted to announce that Partner, Hsu Min Chung, has been recognised in the IAM Global Leaders 2027 guide, a prestigious ranking that highlights some of the world’s leading …

Read article
Event - 28th October 2026

HGF Attending the KINPA Conference 2026

HGF is pleased to be attending the KINPA Conference 2026, taking place on 28 October in Seoul, South Korea. Recognised as Korea’s largest intellectual property gathering, the conference brings together …

Event details
Event - 17th - 19th November 2026

HGF Attending IPBC Asia 2026

HGF is pleased to announce that Partner, Dr Jennifer Uno, will be attending IPBC Asia 2026, taking place from 17-19 November 2026 in Tokyo, Japan. The event is one of …

Event details

HGF Recognised in the Chambers and Partners UK 2027 Guide

HGF is proud to announce that we have once again been recognised in the Chambers and Partners UK 2027 Guide, with outstanding rankings for both the firm and individual practitioners …

Read article
Event - 4th November 2026

IAM Navigating the UPC conference

HGF are gold sponsors of the IAM Live Navigating the UPC conference. IAM Live: Navigating the UPC returns to Paris in November bringing together over 180 industry leaders for an …

Event details